Probleme bei der Darstellung von ARIVA.DE?

  • Laden unsere Charts bei Ihnen nicht?
  • Wird unser Forum bei Ihnen nicht korrekt dargestellt?

Sie nutzen einen Adblocker, der hierfür verantwortlich ist. Hierauf hat ARIVA.DE leider keinen Einfluss. Bitte heben Sie die Blockierung von ARIVA.DE in Ihrem Adblocker auf.

Probleme bei der Darstellung von ARIVA.DE?

Top-Thema

28.03.17
ROUNDUP/Aktien New York Schluss: Dow beendet achttägige Minusserie - Gute Daten

China Biologic Products to Report Fourth Quarter and Fiscal Year 2016 Financial Results

Dienstag, 14.02.2017 22:10 von

PR Newswire

BEIJING, Feb. 14, 2017 /PRNewswire/ -- China Biologic Products, Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that the Company plans to release fourth quarter and Fiscal Year 2016 financial results on Thursday, February 23, 2017 after the market closes.

The Company's management will hold a conference call at 7:30 a.m. ET on Friday, February 24, 2017, which is 8:30 p.m., Beijing Time on February 24, 2017, to discuss fourth quarter and fiscal year 2016 results. Listeners may access the call by dialing:

US: 

1 888 346 8982

International:

1 412 902 4272

Hong Kong: 

800 905 945

China:

400 120 1203

A telephone replay will be available one hour after the conclusion of the conference call through March 3, 2017. The dial-in details are:

US: 

1 877 344 7529

International: 

1 412 317 0088

Passcode: 

10101712

A live and archived webcast of the conference call will be available through the Company's investor relations website at http://chinabiologic.investorroom.com/.

About China Biologic Products, Inc.

China Biologic is a leading plasma-based biopharmaceutical company in China. The Company's products are used as critical therapies during medical emergencies and for the prevention and treatment of life-threatening diseases and immune-deficiency related diseases. China Biologic is headquartered in Beijing and manufactures over 20 different dosages of plasma-based products through its majority-owned subsidiary, Shandong Taibang Biological Products Co., Ltd., and its wholly-owned subsidiary, Guizhou Taibang Biological Products Co., Ltd. The Company also has an equity investment in Xi'an Huitian Blood Products Co., Ltd. The Company sells its products to hospitals and inoculation centers, as well as distributors, in China. For additional information, please see the Company's website, www.chinabiologic.com.

Contact:

China Biologic Products, Inc.
Mr. Ming Yin
Senior Vice President 
Phone: +86-10-6598-3099
Email: ir@chinabiologic.com

ICR Inc.
Mr. Bill Zima
Phone: +86-10-6583-7511 or +1-646-405-5191
E-mail: william.zima@icrinc.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/china-biologic-products-to-report-fourth-quarter-and-fiscal-year-2016-financial-results-300406894.html

SOURCE China Biologic Products, Inc.